Fuyuan Pharmaceutical (601089.SH): Lactofructose oral solution obtained drug registration certificate

Gelonghui, April 30, 丨 Fuyuan Pharmaceutical (601089.SH) announced that its wholly-owned subsidiary Fuyuan Pharmaceutical Co., Ltd. has received the “Drug Registration Certificate” for lactulose oral solution (specification: 15ml: 10g) issued by the State Drug Administration. This product is suitable for: 1. Chronic or habitual constipation: Regulates the physiological rhythm of the colon. 2. Hepatic encephalopathy: used to treat and prevent hepatic coma or pre-coma states.

Gelonghui FinanceApr 30 03:58 ET

Fuyuan Pharmaceutical (601089.SH): Net profit of 133 million yuan in the first quarter increased 16.60% year over year

On April 23, Ge Longhui Pharmaceutical (601089.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 803 million yuan, down 2.01% year on year; net profit attributable to shareholders of listed companies was 133 million yuan, up 16.60% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 124 million yuan, up 11.86% year on year; basic earnings per share were 0.28 yuan.

Gelonghui FinanceApr 23 04:35 ET

Fuyuan Pharmaceutical (601089.SH): The company's main products in the field of diabetes drugs are reprignide tablets, etc.

Gelonghui, April 17丨Fuyuan Pharmaceutical (601089.SH) said on the investor interactive platform that the company's main products in the field of diabetes drugs are regaglinide tablets, gliclazide sustained-release tablets, acarbose tablets, etc.

Gelonghui FinanceApr 17 03:37 ET

Fuyuan Pharmaceutical (601089.SH): Has not cooperated with the Pangu Grand Model

Gelonghui, April 2 | Fuyuan Pharmaceutical (601089.SH) said on an interactive platform that the company has not cooperated with the Pangu Big Model at present.

Gelonghui FinanceApr 2 05:15 ET

Fuyuan Pharmaceutical (601089.SH): A total of 2.09% shares have been repurchased at a cost of 149 million yuan

Gelonghui, March 25, 丨 Fuyuan Pharmaceutical (601089.SH) announced that as of March 25, 2024, the company had repurchased a total of 1.018 million shares through centralized bidding transactions, accounting for about 2.09% of the company's total share capital, an increase of 0.70% compared with the previous disclosure. The minimum transaction price was RMB 14.37 per share, the highest transaction price was RMB 15.59 yuan/share, and the total amount of capital paid was RMB 149 million (not including transaction fees).

Gelonghui FinanceMar 25 05:16 ET

Fuyuan Pharmaceutical (601089.SH): A total cost of 98.166,600 yuan to buy back 1.39% of the shares

Gelonghui, March 7, 丨 Fuyuan Pharmaceutical (601089.SH) announced that as of March 7, 2024, the company had repurchased 6,687,200 shares through centralized bidding transactions. The repurchased shares accounted for about 1.39% of the company's total share capital, an increase of 0.84% compared with the previous disclosure. The highest transaction price was 14.91 yuan/share, the lowest price was 14.37 yuan/share, and the total amount paid was 98,166,590.92 yuan.

Gelonghui FinanceMar 7 04:23 ET